Table 1.
Characteristics of the overall cohort.
| n = 525 | |
|---|---|
| Age (y) | 67.1 ± 10.0 |
| Sex (n) | |
| Male | 394 |
| Female | 131 |
| Primary sites (n) | |
| Lung cancer | 263 (50.1%) |
| Renal-urinary cancer | 117 (22.3%) |
| Head and neck cancer | 45 (8.6%) |
| Malignant melanoma | 43 (8.2%) |
| Gastric cancer | 37 (7.0%) |
| Esophageal cancer | 10 (1.9%) |
| Others | 10 (1.9%) |
| Endocrine-related irAEs (n) | |
| Thyroid irAEs | 34 (6.5%) |
| Secondary adrenal insufficiency | 19 (3.6%) |
| Diabetes mellitus | 2 (0.4%) |
| Others | 0 (0.0%) |
Age is expressed as average (± standard deviation) at the first administration of immune checkpoint inhibitors.
Abbreviation: irAEs immune-related adverse events.